SCHEMBL23857686

SCHEMBL23857686

CCOC(=O)CC1CNC(=O)C1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
POLB P06746 2/20 0.41
TSHR P16473 2/20 0.38
CYP1A2 P05177 1/20 0.38
KMT2A Q03164 2/20 0.38
SYK P43405 1/20 0.37
ALDH1A1 P00352 4/20 0.36
MAPT P10636 2/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HTT P42858 1/20 0.36
MIF P14174 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29067911 0.85 POLB (0.43) PDE4APDE4BPDE4CPDE4DPOLB
SCHEMBL4400125 0.84 POLB (0.45) PDE4APDE4BPDE4CPDE4DPOLB
SCHEMBL29129902 0.83 NAAA (0.39) PDE4APDE4BPDE4CPDE4DSYK
SCHEMBL523230 0.83 BRD4 (0.50) PDE4APDE4BPDE4CPDE4DKMT2A
SCHEMBL11260375 0.81 POLB (0.46) POLBTSHRCYP1A2KMT2AALDH1A1
SCHEMBL11719452 0.80 PDE4A (0.41) PDE4APDE4BPDE4CPDE4DPOLB
SCHEMBL11719460 0.80 PDE4A (0.41) PDE4APDE4BPDE4CPDE4DPOLB
SCHEMBL11719447 0.80 PDE4A (0.41) PDE4APDE4BPDE4CPDE4DPOLB
SCHEMBL14004149 0.77 SYK (0.35) PDE4APDE4BPDE4CPDE4DSYK
SCHEMBL3298172 0.74 GAA (0.44) POLBTSHRCYP1A2ALDH1A1MGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126855-B1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2024-04-24 EP disclosed
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-06-01 US disclosed
EP-4126855-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2023-02-08 EP disclosed
CN-115298176-A Compounds and their use in the treatment of bacterial infections 豪夫迈·罗氏有限公司 2022-11-04 CN disclosed
WO-2021190727-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2021-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION LTB4R, C5, C3AR1 PDE4A 1540/4885PDE4B 725/4885PDE4C 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.